Host genetics and the gut microbiome, in a collaborative fashion, influence metabolic phenotypes. Recent studies suggest that the characteristics of the gut microbiota are altered in patients with ...
Altimmune ($ALT) announced an update on their ongoing clinical study. Altimmune’s IMPACT trial, officially titled “A Phase 2, Multicenter, ...
The Food and Drug Administration on Thursday approved the first-ever treatment for a common and potentially deadly form of liver disease that affects millions worldwide. The FDA's decision means ...
--Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis, today announced results from new analyses of the Phase 3 ...
CONSHOHOCKEN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis ...
Imagine sitting in a doctor’s office and being told you have “non-alcoholic” liver disease. Before the doctor even finishes explaining what that means, your brain is already doing gymnastics trying to ...
A groundbreaking AI tool, AIM-NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative technology assists pathologists in swiftly and accurately analyzing liver ...
The Food and Drug Administration on Thursday approved the first-ever treatment for a common and potentially deadly form of liver disease that affects millions worldwide. Stream NBC 5 for free, 24/7, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback